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s  u  m  m  a  r  y
5-Fluorouracil  (5-FU)  is  a key  component  in the  treatment  of  many  gastrointestinal  tract  adenocar-
cinomas. Despite  its  proven  therapeutic  efﬁcacy,  this  chemotherapeutic  agent  also  possesses  severaleceived  in revised form 28 February 2012
ccepted 15 March 2012
eywords:
-Fluorouracil
cute coronary syndrome
ardiotoxicity
associated cardiac  toxicities,  including  coronary  vasospasm  and  coronary  thrombosis.  We  report  a case
of acute  coronary  syndrome  with  thrombotic  subtotal  coronary  artery  occlusion  in the  setting  of  home
5-FU infusion  highlighting  the  importance  of  careful  pre-administration  cardiac  evaluation  and  close
monitoring during  drug  administration.
© 2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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Acute coronary syndrome (ACS) precipitated by the adminis-
ration  of 5-ﬂuorouracil (5-FU) is a rare but well-established event
1,2]  and only one of the several side effects of this chemother-
peutic agent. Other cardiotoxicities include cardiomyopathy,
asospastic angina, and malignant arrhythmias [1–5]. Following
n  initial cardiac complication, it is essential to weigh the risks
f  repeat drug administration against the potential for cure of the
alignancy given the effectiveness of this chemotherapeutic reg-
men.  This case report and review of the literature examines the
ardiac  complications of 5-FU and their effect on the therapeutic
ecision-making process.
ase  report
A  55-year-old male with a history of hypertension, hyperlipi-
emia, and recent subtotal gastrectomy for stage IA gastric cancer
eveloped  chest tightness within an hour of the initial administra-
ion  of FOLFOX (5-FU, oxaliplatin, and folinic acid). These symptoms
asted  for only 5 min  and resolved spontaneously following ter-
ination  of the infusion. The infusion was subsequently restarted
ithout  any recurrent chest pain. The patient was sent home with
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ttp://dx.doi.org/10.1016/j.jccase.2012.03.011n infusion pump to receive a continuous infusion of 5-FU for
n  additional 24 h. Six hours later he developed recurrent severe
hest  pressure with radiation to both arms accompanied by nausea
nd  diaphoresis. On presentation to the emergency department an
lectrocardiogram (ECG) demonstrated anterolateral ST-segment
epressions and T wave inversions. His infusion was stopped and
e was treated with sublingual nitroglycerine with complete symp-
om resolution. His initial troponin-I was  elevated at 0.19 ng/mL,
ater  peaking at 28 ng/mL.
He was admitted to the coronary care unit and a left heart
atheterization was performed demonstrating mildly depressed
lobal  left ventricular systolic function, nonobstructive disease
n  the left anterior descending and right coronary arteries and a
hrombotic subtotal occlusion of the left circumﬂex coronary artery
Fig. 1A). He underwent successful mechanical thrombectomy and
lacement of a bare metal stent (Fig. 1B) without complication. Dur-
ng post-procedure observation he had no symptom recurrence and
as discharged on hospital day 4 on a beta-blocker, angiotensin-
onverting enzyme inhibitor, aspirin, statin, and clopidogrel.
iscussion
The  chemotherapeutic agent 5-FU is a ﬂuoropyrimidine
ntimetabolite agent key to several chemotherapy regimens,
articularly in the treatment of gastrointestinal tract adenocar-
inomas.  There is evidence that 5-FU therapy combined with
urgical  resection offers an impressive absolute risk reduction of
-year mortality of 5.7% [6]. Unfortunately 5-FU also has poorly
vier Ltd. All rights reserved.
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Figure 1. (A) Angiogram demonstrating thrombotic subtotal occlusion of the
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seft circumﬂex coronary artery on right anterior oblique caudal projection. (B)
ngiogram in the same projection following percutaneous coronary intervention
ith  a bare metal stent.
eﬁned cardiotoxic effects. Various studies demonstrate direct
ndothelial  cardiotoxicity, arterial vasospasm, cardiomyopathy
ith signiﬁcant left ventricular systolic dysfunction, sinoatrial
nd  atrioventricular node dysfunction, and ventricular arrythmias
5,7,8].
The  precise etiology and pathophysiology of 5-FU cardiotoxicity
s  still unknown and based primarily on limited animal studies, case
eports,  and small clinical studies. Clinically signiﬁcant coronary
asospasm causing myocardial ischemia is the most commonly
uspected mechanism, occurring in 1.2–18% of cases, even in the
bsence  of coronary artery disease [1,3,7,9,10]. Both animal and
uman studies demonstrate a dose-dependent vasospasm that
eases  with cessation of drug administration [2,7]. Experimental
vidence also supports a direct toxic effect of 5-FU on the coro-
ary  endothelium [11] and a hypercoagulable state which together
recipitate  acute thrombotic events [10,12].
A study by Rezkalla et al. [4] demonstrated ischemic and
rrhythmic ECG changes, including ST-segment deviation and
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T-prolongation, in nearly 68% of patients receiving infusions of
-FU. And while overall cardiac toxicity with 5-FU administration
anges from 1 to 3%, it approaches 5% in patients with underlying
eart  disease [2,4]. One retrospective examination of 377 case
eports  revealed acute myocardial infarction in 22% of patients
uring  5-FU administration [8]. Another prospective study of 26
atients suggested infarction by ECG and symptom criteria in 35%
f patients receiving 5-FU [1].
It is believed that the newer prolonged infusion schedules of
-FU  can lead to even more vasospastic and thrombotic compli-
ations  [9]. Additionally, the median time for symptom initiation
s  12 h following initiation of the infusion [3], although in animal
tudies,  the median time was reported to be as long as 48 h [13]
nd  have a variable point of symptom onset. Our patient, although
arly  in presentation, is still within the range of 5-FU-induced
hrombosis. Although our patient experienced chest pain during his
nitial observed 5-FU infusion, as there was no recurrence with later
esumption  of the infusion, he was sent home with a continuous
nfusion pump. In retrospect, it may  have been preferable to con-
uct  a more prolonged observation with ECG and hemodynamics
uring reinitiation of his 5-FU infusion prior to home administra-
ion.  Additionally, several studies have demonstrated that having a
ower dose of 5-FU is preferable if absolutely necessary [14], which
s  likely why this patient went home on a lower dose infusion pump
nd  did well post infusion.
This  case highlights the importance of the pre-chemotherapy
istory and physical examination. Patients should have a care-
ul  evaluation for cardiovascular risk factors as well as subclinical
oronary artery disease or cardiomyopathies which may  be exac-
rbated by 5-FU administration. Future administration of 5-FU in
ur patient is controversial. However, there is no absolute evidence
hat  repeat 5-FU administration is contraindicated, although it is
ypical practice to at least lower the infusion dose or add antiangi-
als  such as nitrates or calcium-channel blockers [14]. And in this
ase, the culprit coronary lesion was treated successfully with per-
utaneous  coronary intervention and angiography demonstrated
inimal residual coronary artery disease in the other territories.
his  patient did run a risk of having potential in-stent thrombosis,
long  with de novo lesions (particularly in the left anterior descend-
ng  artery region) with further 5-FU; ultimately, this patient was
reated  with aggressive risk factor modiﬁcation as well as aspirin
nd  statin for their antithrombotic and plaque stabilization proper-
ies  in order to continue his chemotherapy regimen. He continued
-FU  therapy under close monitoring in an effort to achieve com-
lete  cure of his malignancy and experienced no further treatment
omplications.
onclusions
With  the demonstrated efﬁcacy of 5-FU based chemotherapeu-
ic regimens more patients may  expect to receive these agents in
he future, oftentimes via home infusion. Thus it is important for
linicians  to be aware of the various rare, but potentially serious,
dverse  cardiac effects. A high level of alertness is required when
onsidering  5-FU based regimens. Cardiovascular risk factors and
rior history of cardiac disease should be investigated and patients
ounseled  appropriately. Ambulatory patients should be advised
o  seek medical attention without delay in the event of symptoms.
npatients should be observed closely and 5-FU administration dis-
ontinued if cardiac symptoms develop. A rechallenge with 5-FU
hould  be reserved for those patients in whom there is no reason-
ble  alternative therapy and only under close monitoring. This case
ighlights  the cardiotoxic effects of 5-FU and the cost-beneﬁt anal-
sis of continuing this cardiotoxic chemotherapeutic agent in the
etting of intervened coronary artery disease.
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